PubMed Health⌕ Search

Biomedical subjects

F Saborowski

Publications and source records attributed to F Saborowski.

At least 19 recordsLinked to original sources
PubMed1991

[Hypercalcemia in florid pulmonary and cervical lymph node tuberculosis].

A 57-year-old man with a history of tuberculosis (TB of the knee-joint 44 years ago and open pulmonary TB six months ago with poor patient drug compliance) had lost 10 kg in weight during the preceding six months. In addition, firm lymph-node swellings with redness of the overlying skin and a skin fistula developed on the right side of the neck. There was mild hypercalcaemia (albumin-corrected serum calcium concentration 2.59 mmol/l) and hyperphosphataemia (2.0 mmol/l) with low-normal serum concentrations of parathormone and of 25-hydroxy-vitamin D3 (14 ng/ml). Serum 1,25-dihydroxy-vitamin D3 concentration was reduced (16 ng/l). The activity of osseous isoenzyme of alkaline phosphatase was normal (19 U/l) and skeletal scintigraphy revealed no abnormality. The cervical lymph-nodes were excised (histology: active caseous lymph-node TB). Tuberculostatic treatment was begun with daily doses of 0.3 g isoniazid, 0.45 g rifampicin, 1.2 g ethambutol and 1.5 g pyrazinamide. Serum calcium concentration rose to 3.22 mmol/l (albumin-corrected) in the first two weeks, even though the patient was on a low-calcium diet. The various concentrations subsequently decreased, but remained slightly elevated throughout the period of observation (11 weeks). This is thus a case of TB-associated hypercalcaemia which was not caused by 1,25-dihydroxy-vitamin D3 or bone destruction.

Alcoholism↗
PubMed1991

[Silent myocardial ischemia in long-term ECG with various mani festations of coronary heart disease].

Silent myocardial ischaemia seems to be of prognostic value in coronary artery disease. We examined 47 patients with coronary artery disease: 1. 20 patients with a history of myocardial infarction (MI), 2. 15 patients with chronic stable angina pectoris without a history of myocardial infarction (sAP), and 3. twelve patients with unstable angina with or without a history of myocardial infarction (uAP). Horizontal and downsloping ST-segment-depressions greater than or equal to 1 min and greater than or equal to 0.1 mV were defined as significant. There were 132 ST-segment-depressions, the relation between symptomatic and asymptomatic being 1:7.3, in MI 1:6.2, in sAP 1:5.3, in uAP 1:14. Heart rate increased before beginning of ST-segment-depression in 74% in MI, in 86% in sAP, but only in 38% in uAP. In sAP ST-segment-depressions were smaller (14% greater than 0.2 mV, none greater than 0.3 mV) than in patients with MI (42% greater than 0.2 mV, 12% greater than 0.3 mV) and uAP (25% greater than 0.2 mV, 9% greater than 0.3 mV). Mean duration of ST-segment-depression was 15.3 +/- 11.7 min in sAP (2 to 49 min), 28.5 +/- 35.6 min in MI (2 to 168 min), and 41.2 +/- 40 min in iAP (2 to 140 min). ST-segment-depressions in MI and sAP showed a circadian rhythm with a peak at midday and in the early evening and a small amount of ST-segment-depressions at night. In uAP ST-segment-depressions did not show that circadian variation. The number of ST-segment-depressions was higher in uAP than in MI and sAP.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1991

[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].

Hemodynamic measurements were done in 42 patients with congestive heart failure of NYHA classes III and IV after administration of the phosphodiesterase inhibitors amrinone und enoximone. Amrinone decreases mean arterial pressure (-4%), right atrial pressure (-39%), and systemic vascular resistance (-23%), while cardiac index and stroke volume index increase to 27% and 26%, respectively; heart rate is nearly unchanged. Enoximone administration in a dose of 1 mg/kg bw produces an increase in cardiac index of 13%, an increase in heart rate of 12%, and a decrease of systemic vascular resistance of 13%, whereas stroke volume index is unchanged. Enoximone in a dose of 1.5 mg/kg bw increases heart rate (+ 9%), cardiac index (+ 33%), and stroke volume index (+ 21%), and decreases systemic vascular resistance (-26%). The hemodynamic profile of amrinone and enoximone in an equal dose shows only slight differences. Furthermore, phosphodiesterase inhibitors produce an increase of cardiac index (+ 19%) and stroke volume index (+ 17%) in patients with pump failure having already received dopamine and dobutamine.

Aged↗
PubMed1990

[Central hemodynamics of a new positive inotropic substance, adibendan. Data from a dose-finding study].

Central Hemodynamics from the New Positive-inotrope Substance Adibendan/An open dose-finding study We investigated the influence of Adibendan which is a new phophodiesterase inhibitor on central hemodynamics in an open dose-finding study. 10 patients with chronic heart failure NYHA II-IV (mean age 67 +/- 5 years) got Adibendan i.v. A maximum increase in cardiac index from 2.3 +/- 0.5 to 3.2 +/- 0.5 l/min.m2 (p less than 0.001) was seen after a cumulative dosage of 0.916 +/- 0.571 mg at a time interval of 107 +/- 43 min after injection of the first dosage of 0.125 mg. There was a pronounced increase in stroke volume index from 30 +/- 6 to 40 +/- 8 ml/m2 (p less than 0.01). Heart rate raised by 5% which was not significant. Systemic vascular resistance dropped by 30% from 1693 +/- 720 to 1177 +/- 292 dyn.s.cm-5 (p less than 0.05), pulmonary vascular resistance by 39% from 755 +/- 273 to 463 +/- 199 dyn.s.cm-5 (p less than 0.001). Blood pressure and right atrial pressure did not alter. Mean pulmonary artery pressure dropped by 14% from 37 +/- 7 to 32 +/- 11 mmHg. We conclude that Adibendan improves cardiac index markedly and causes a modest decrease in mean pulmonary artery pressure.

Aged↗
PubMed1989

Cardiac function in endocrine diseases: I. Acromegaly.

The aim of our echocardiographic study was to characterize cardiac function and anatomy of 14 acromegalics (A: 9 women, 5 men; mean age: 42.4 yrs) more closely. The duration of acromegaly in 4 of these patients was between 3 and 12 years; the disease was diagnosed for the first time in the other patients. Double M-mode echocardiography was performed in all patients and the results compared with data obtained from a control group of 24 healthy volunteers (N: 22 men, 2 women; mean age: 23 yrs). The mean left ventricular diameter at end-diastole was greater in the acromegalics than in the controls (A: 55 +/- 6 mm, N: 50 +/- 4 mm; p less than 0.005, means +/- SD). After correction for age and body surface area, it, however, was outside the 95% confidence interval in 5 patients. Left ventricular hypertrophy was present in 3 patients, one of whom had coexistent arterial hypertension. A total of 3 patients were hypertensive. Significantly higher values for the maximal velocity of systolic wall thickening (A: 6.1 +/- 0.6 cm/s, N: 4.2 +/- 0.6 cm/s, p less than 0.001) and diameter change (A: 12.4 +/- 2.0 cm/s, N: 10.6 +/- 1.0 cm/s, p less than 0.005) indicate increased contractility with concurrently increased relaxation; fractional shortening did not differ significantly (A: 38 +/- 5%, N: 37 +/- 5%, ns). The isovolumetric relaxation period at diastole was slightly longer in the acromegalics (A: 70 +/- 17 ms, N: 61 +/- 13 ms, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Acromegaly↗
PubMed1989

Acute effects of enoximone in chronic heart failure.

In 19 patients with chronic heart failure in NYHA stages III and IV, hemodynamic measurements were made using a Swan-Ganz catheter before and 15 and 30 min after intravenous administration of enoximone. Group A (n = 10) received 1.0 mg of enoximone/kg of body weight and group B (n = 9) received 1.5 mg of enoximone/kg of body weight. In group A, there was a rise in the pulse rate of 13% and in the cardiac index of 13% with unchanged stroke volume index. At constant mean arterial pressure, the mean right atrial pressure fell by 28%, the mean pulmonary arterial pressure by 11%, the total peripheral resistance by 13%, and the total pulmonary resistance by 21% after 30 min. In group B, the pulse rate rose by 9.8%, the mean blood pressure by 2.7%, the cardiac index by 31.4%, and the stroke volume index by 18.4% 30 min after administration of enoximone, whereas a fall in the mean right atrial pressure by 57.4%, the mean pulmonary arterial pressure by 28.6%, the total peripheral resistance by 26.0%, and the total pulmonary resistance by 45.3% could be shown. At a low dosage of enoximone, the vasodilatory effects of this substance are most prominent, whereas an increase in the pumping performance of the heart could be clearly demonstrated in higher dose ranges.

Aged↗
PubMed1989

[Effect of pimobendan on peripheral hemodynamics].

Peripheral hemodynamics and some metabolic parameters were studied in 20 patients with coronary artery disease (x = 59 +/- 9 y) and in 20 healthy volunteers (x = 25 +/- 3 y) at rest and after isometric handgrip exercise both before and after administration of pimobendan or placebo using a randomized, double-blind study. Forearm blood flow was measured using venous occlusion plethysmography. In pimobendan treated patients and volunteers an increase in forearm blood flow between 9% and 38% could be noticed. The increase in forearm blood flow was significant in comparison to placebo only, in volunteers under resting conditions. Heart rate increased significantly by 14-19% in all groups after administration of pimobendan. There were no alterations in blood pressure. Local resistance in forearm fell by 13-22%. Pimobendan did not change metabolic parameters.

Adult↗
PubMed1975

Determination of mean whole body intracellular pH in unanesthetized dogs.

In order to determine mean whole body pHi in unanesthetized dogs, assumptions on the urinary and intestinal excretion of DMO, the total loss of an injected single dose of [14C] DMO, and the distribution kinetics of DMO were tested experimentally. Urinary excretion of DMO was almost negligible. The best assumption on the total loss of DMO was based on the exponential decay observed over a period of 1 to 4 weeks. The biological half-life of DMO was 5 days, the time constant being --0.14 d-1. The extracellular distribution of DMO was considered to equal that of [3H] inulin. Between 1 and 7 hours after an injection of inulin in nephrectomized dogs the distribution volume increased linearly from 16% of the body weight after 2 hours to 21% after 6 hours. Based on these experimental results, pHi was determined in 16 unanesthetized dogs. 120 min after the injection of DMO pHi was 7.05 and 430 min after the injection pHi was 7.11. It is concluded that the assumption made allow the estimation of pHi in unanesthetized dogs over a period of 1 to 7 hours.

Acid-Base Equilibrium↗